$IMAB
I-Mab

2023 Q4 Form 20-F Financial Statement

#000110465924054452 Filed on April 30, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023
Revenue $27.64M $27.64M
YoY Change -110.11% -112.48%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0%
Gross Profit $27.64M $27.64M
YoY Change -110.11% -111.11%
Gross Profit Margin 100.0% 100.0%
Selling, General & Admin $453.0M $453.0M
YoY Change 38.19% -37.1%
% of Gross Profit 1638.75% 1638.75%
Research & Development $810.6M $810.6M
YoY Change 79.23% -10.42%
% of Gross Profit 2932.45% 2932.45%
Depreciation & Amortization $3.400M
YoY Change -8.11%
% of Gross Profit 12.3%
Operating Expenses $1.264B $1.264B
YoY Change 61.99% -22.24%
Operating Profit -$1.236B -$1.236B
YoY Change 17.32% -34.04%
Interest Expense -$28.99M -$28.99M
YoY Change -87.72% -92.94%
% of Operating Profit
Other Income/Expense, Net -$38.11M -$38.11M
YoY Change -48.94% -69.9%
Pretax Income -$1.466B -$1.466B
YoY Change 7.43% -39.21%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.466B -$1.466B
YoY Change 7.38% -39.23%
Net Earnings / Revenue -5302.03% -5302.03%
Basic Earnings Per Share -$1.08
Diluted Earnings Per Share -$7.19 -$7.19
COMMON SHARES
Basic Shares Outstanding 185.6M 191.4M
Diluted Shares Outstanding 191.4M

Balance Sheet

Concept 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.285B $2.285B
YoY Change -33.77% -33.77%
Cash & Equivalents $2.141B $2.141B
Short-Term Investments $143.2M $143.2M
Other Short-Term Assets $52.00M $52.00M
YoY Change -70.63% -70.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.337B $2.337B
YoY Change -35.57% -35.57%
LONG-TERM ASSETS
Property, Plant & Equipment $82.91M $82.91M
YoY Change -33.12% -33.12%
Goodwill
YoY Change
Intangibles $16.64M
YoY Change -3.49%
Long-Term Investments $12.08M $12.08M
YoY Change -60.84% -60.84%
Other Assets $63.20M $63.20M
YoY Change 479.19% 479.19%
Total Long-Term Assets $276.3M $276.3M
YoY Change -38.21% -38.21%
TOTAL ASSETS
Total Short-Term Assets $2.337B $2.337B
Total Long-Term Assets $276.3M $276.3M
Total Assets $2.613B $2.613B
YoY Change -35.86% -35.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $357.8M $357.8M
YoY Change -41.17% -41.17%
Accrued Expenses $21.89M $21.89M
YoY Change -8.64% -8.64%
Deferred Revenue $310.0K
YoY Change -75.36%
Short-Term Debt $29.97M $29.97M
YoY Change 58.1% 58.1%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $411.8M $411.8M
YoY Change -37.58% -37.58%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $483.0M $483.0M
YoY Change 19.08% 19.08%
Total Long-Term Liabilities $483.0M $483.0M
YoY Change 19.08% 19.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $411.8M $411.8M
Total Long-Term Liabilities $483.0M $483.0M
Total Liabilities $894.8M $894.8M
YoY Change -16.01% -16.01%
SHAREHOLDERS EQUITY
Retained Earnings -$1.173B
YoY Change 17.89%
Common Stock $1.381B
YoY Change -0.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.718B $1.718B
YoY Change
Total Liabilities & Shareholders Equity $2.613B $2.613B
YoY Change -35.86% -35.86%

Cashflow Statement

Concept 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.466B -$1.466B
YoY Change 7.38% -39.23%
Depreciation, Depletion And Amortization $3.400M
YoY Change -8.11%
Cash From Operating Activities -$183.8M
YoY Change 14.95%
INVESTING ACTIVITIES
Capital Expenditures $1.599M
YoY Change -75.94%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $14.44M
YoY Change -78.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.066M
YoY Change -82.64%
NET CHANGE
Cash From Operating Activities -183.8M
Cash From Investing Activities 14.44M
Cash From Financing Activities 1.066M
Net Change In Cash -156.4M
YoY Change 406.75%
FREE CASH FLOW
Cash From Operating Activities -$183.8M
Capital Expenditures $1.599M
Free Cash Flow -$185.4M
YoY Change 11.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001778016
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
190879919
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
185613662
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
778000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
778000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
778000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
778000
CY2023Q4 us-gaap Supplier Finance Program Obligation Noncurrent Statement Of Financial Position Extensible Enumeration
SupplierFinanceProgramObligationNoncurrentStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023 dei Document Type
DocumentType
20-F
CY2023 dei Document Registration Statement
DocumentRegistrationStatement
false
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Document Shell Company Report
DocumentShellCompanyReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39173
CY2023 dei Entity Registrant Name
EntityRegistrantName
I-MAB
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2440 Research Boulevard, Suite 400
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2023 dei Entity Address Country
EntityAddressCountry
US
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
185613662
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Document Accounting Standard
DocumentAccountingStandard
U.S. GAAP
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023 dei Auditor Name
AuditorName
PricewaterhouseCoopers Zhong Tian LLP
CY2023 dei Auditor Location
AuditorLocation
Shanghai, China
CY2023 dei Auditor Firm
AuditorFirmId
1424
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3214005000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2141445000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
301616000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
96764000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
235429000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
143221000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
20172000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80278000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52003000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7325000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3626476000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2336669000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
329113000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
58913000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8298000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60841000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36511000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5142000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63125000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46400000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6535000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118888000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118110000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16635000
CY2022Q4 us-gaap Goodwill
Goodwill
162574000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
30850000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
12082000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1702000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10911000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4282000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
603000
CY2022Q4 us-gaap Assets
Assets
4073665000
CY2023Q4 us-gaap Assets
Assets
2612967000
CY2023Q4 us-gaap Assets
Assets
368028000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
18956000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
29970000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
4221000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
706572000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
357754000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50389000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8677000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2200000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
310000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23961000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21890000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3083000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
758166000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
411814000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58003000
CY2022Q4 imab Put Right Liabilities
PutRightLiabilities
88687000
CY2023Q4 imab Put Right Liabilities
PutRightLiabilities
98110000
CY2023Q4 imab Put Right Liabilities
PutRightLiabilities
13819000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
267878000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
292124000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41145000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32069000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23099000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3253000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16963000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
69664000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9811000
CY2022Q4 us-gaap Liabilities
Liabilities
1163763000
CY2023Q4 us-gaap Liabilities
Liabilities
894811000
CY2023Q4 us-gaap Liabilities
Liabilities
126031000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
190879919
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
185613662
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
132000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
133000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
21249000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
56803000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
8001000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
9579375000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
9804379000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1380918000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
213794000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
298291000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
42013000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1465694000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-206439000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3154000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6862150000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8327844000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1172952000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2909902000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1718156000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
241997000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4073665000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2612967000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
368028000
CY2021 us-gaap Revenues
Revenues
88026000
CY2022 us-gaap Revenues
Revenues
-221563000
CY2023 us-gaap Revenues
Revenues
27644000
CY2023 us-gaap Revenues
Revenues
3893000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
46432000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
27237000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1212958000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
904901000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
810646000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114177000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
899943000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
815766000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
453017000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63806000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
162574000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
22898000
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-2071307000
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1969467000
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1398593000
CY2023 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-196988000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
21333000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
26908000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
51749000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
7289000
CY2021 us-gaap Interest Expense
InterestExpense
0
CY2022 us-gaap Interest Expense
InterestExpense
9000
CY2023 us-gaap Interest Expense
InterestExpense
722000
CY2023 us-gaap Interest Expense
InterestExpense
102000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
83162000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126587000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38109000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5368000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-367883000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-437465000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-80019000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11270000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2334695000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2506620000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
697000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2331541000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2507317000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1465694000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-206439000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2331541000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2507317000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1465694000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-206439000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2331541000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2507317000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1465694000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-206439000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2022 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2023 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-135717000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
400304000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84497000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11901000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2467258000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2107013000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1381197000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-194538000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2331541000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2507317000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1465694000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-206439000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174707055
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189787292
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
191423850
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
191423850
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174707055
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189787292
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191423850
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191423850
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.35
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.21
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.66
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.35
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.21
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.66
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5627145000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-135717000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2331541000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
608609000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2909902000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2909902000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84497000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51315000
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
8551000
CY2021 imab Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
672664000
CY2021 imab Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate
ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate
58534000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2788000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1465694000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
193002000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4559560000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4559560000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
400304000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2507317000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
357148000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44650000
CY2022 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
21249000
CY2022 imab Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate
ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate
76806000
CY2023 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
61260000
CY2023 imab Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate
ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate
54921000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1718156000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2331541000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2507317000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1465694000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-206439000
CY2021 us-gaap Depreciation
Depreciation
13776000
CY2022 us-gaap Depreciation
Depreciation
25340000
CY2023 us-gaap Depreciation
Depreciation
23949000
CY2023 us-gaap Depreciation
Depreciation
3373000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
778000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
778000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
778000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
110000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
162574000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
22898000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-288000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-117000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-488000
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-69000
CY2021 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
-16628000
CY2022 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
-34260000
CY2023 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
7888000
CY2023 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
1111000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-367883000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-437465000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-80019000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-11270000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
608609000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
357148000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
193002000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
27184000
CY2021 imab Amortization Of Right Of Use Assets And Interest Of Lease Liabilities
AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
19582000
CY2022 imab Amortization Of Right Of Use Assets And Interest Of Lease Liabilities
AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
37698000
CY2023 imab Amortization Of Right Of Use Assets And Interest Of Lease Liabilities
AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
27986000
CY2023 imab Amortization Of Right Of Use Assets And Interest Of Lease Liabilities
AmortizationOfRightOfUseAssetsAndInterestOfLeaseLiabilities
3942000
CY2022 imab Recognition Of Deferred Cost For Planned Dual Listing
RecognitionOfDeferredCostForPlannedDualListing
14613000
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-7905000
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-1113000
CY2021 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-30360000
CY2022 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
13549000
CY2023 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-26461000
CY2023 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-3727000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-97417000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33081000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
26389000
CY2022 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-253780000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5155000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-109226000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35863000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5051000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27237000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-27237000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51315000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
152101000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
109863000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-342715000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-48270000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
224000000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
52555000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
17769000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2503000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5959000
CY2022 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2029000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6212000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-875000
CY2021 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-7509000
CY2021 imab Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-18667000
CY2022 imab Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-35707000
CY2023 imab Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-22089000
CY2023 imab Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-3111000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-973093000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1102805000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1304950000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-183798000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29932000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45830000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11351000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1599000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
26000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
19000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2021 imab Capital Injection In An Affiliate
CapitalInjectionInAnAffiliate
6000000
CY2023 imab Capital Injection In An Affiliate
CapitalInjectionInAnAffiliate
6000000
CY2023 imab Capital Injection In An Affiliate
CapitalInjectionInAnAffiliate
845000
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
9482040000
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
7911518000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
1005249000
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
141586000
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10173314000
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
7407332000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
885580000
CY2023 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
124731000
CY2023 us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
178000
CY2023 us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
25000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-727206000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
458382000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
102515000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14439000
CY2021 imab Payments Of The Issuance Cost In Relation To Private Placement
PaymentsOfTheIssuanceCostInRelationToPrivatePlacement
128786000
CY2021 imab Payments Of Cost In Relation To Planned Dual Listing
PaymentsOfCostInRelationToPlannedDualListing
9820000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
672664000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44650000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2788000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
393000
CY2021 us-gaap Proceeds From Issuance Of Common Limited Partners Units
ProceedsFromIssuanceOfCommonLimitedPartnersUnits
8551000
CY2022 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
18956000
CY2023 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
118853000
CY2023 us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
16740000
CY2023 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
48926000
CY2023 us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
6892000
CY2022 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
21249000
CY2023 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
61260000
CY2023 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
8628000
CY2023 imab Prepayments For Repurchase Of Equity
PrepaymentsForRepurchaseOfEquity
3883000
CY2023 imab Prepayments For Repurchase Of Equity
PrepaymentsForRepurchaseOfEquity
547000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
593924000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42357000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7572000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1066000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-128771000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
389203000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84452000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11896000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1235146000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-212863000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1110411000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-156397000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4758778000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3523632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3310769000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466311000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3523632000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3310769000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2200358000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
309914000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
18667000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
35707000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
22089000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
3111000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
118436000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9888000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11108000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1565000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9077000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
697000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
704000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
99000
CY2021 imab Payables For Purchase Of Property Equipment And Software
PayablesForPurchaseOfPropertyEquipmentAndSoftware
6679000
CY2022 imab Payables For Purchase Of Property Equipment And Software
PayablesForPurchaseOfPropertyEquipmentAndSoftware
7124000
CY2023 imab Payables For Purchase Of Property Equipment And Software
PayablesForPurchaseOfPropertyEquipmentAndSoftware
1226000
CY2023 imab Payables For Purchase Of Property Equipment And Software
PayablesForPurchaseOfPropertyEquipmentAndSoftware
173000
CY2021 imab Accrued Planned Dual Listing Costs Payable
AccruedPlannedDualListingCostsPayable
4793000
CY2022 imab Non Cash Activity Of Recognition On Put Option Liability
NonCashActivityOfRecognitionOnPutOptionLiability
17729000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2.3 Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities and other intangible assets as well as subsequent fair value measurements. Additionally, estimates are used in determining items such as fair value measurements of short-term investments and put right liabilities, impairment of other receivables, long-lived assets, intangible assets and goodwill, useful lives of property, equipment and software, recognition of right-of-use assets and lease liabilities, accrued research and development expenses, cost-to-cost measure of progress for over time performance obligations, variable consideration in collaboration revenue arrangements, valuation of share-based compensation arrangements, deferred tax assets valuation allowances and provision for ongoing litigation. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</p>
CY2023 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3214005000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2141445000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
96764000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
58913000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3310769000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2200358000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
162574000
CY2021 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2022 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2021 us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0
CY2022 us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0
CY2023 us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0
CY2021Q4 us-gaap Grants Receivable
GrantsReceivable
9216000
CY2022Q4 us-gaap Grants Receivable
GrantsReceivable
25470000
CY2023Q4 us-gaap Grants Receivable
GrantsReceivable
5354000
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022Q4 us-gaap Supplies
Supplies
32960000
CY2023Q4 us-gaap Supplies
Supplies
5175000
CY2023Q4 us-gaap Supplies
Supplies
729000
CY2023Q4 imab Prepayments For Stock Repurchase
PrepaymentsForStockRepurchase
3883000
CY2023Q4 imab Prepayments For Stock Repurchase
PrepaymentsForStockRepurchase
547000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1321000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5908000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
832000
CY2022Q4 imab Prepayments To An Affiliate
PrepaymentsToAnAffiliate
8231000
CY2023Q4 imab Prepayments To An Affiliate
PrepaymentsToAnAffiliate
14208000
CY2023Q4 imab Prepayments To An Affiliate
PrepaymentsToAnAffiliate
2001000
CY2022Q4 imab Valueadded Tax Recoverable
ValueaddedTaxRecoverable
8197000
CY2023Q4 imab Valueadded Tax Recoverable
ValueaddedTaxRecoverable
4696000
CY2023Q4 imab Valueadded Tax Recoverable
ValueaddedTaxRecoverable
661000
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
4570000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
4863000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
685000
CY2022Q4 us-gaap Other Assets
OtherAssets
24999000
CY2023Q4 us-gaap Other Assets
OtherAssets
13270000
CY2023Q4 us-gaap Other Assets
OtherAssets
1870000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80278000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52003000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7325000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
116206000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
110008000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15494000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
61583000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
73497000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10352000
CY2022Q4 imab Property Plant And Equipment Net Excluding Construction In Progress
PropertyPlantAndEquipmentNetExcludingConstructionInProgress
54623000
CY2023Q4 imab Property Plant And Equipment Net Excluding Construction In Progress
PropertyPlantAndEquipmentNetExcludingConstructionInProgress
36511000
CY2023Q4 imab Property Plant And Equipment Net Excluding Construction In Progress
PropertyPlantAndEquipmentNetExcludingConstructionInProgress
5142000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6218000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60841000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36511000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5142000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13800000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25300000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23900000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3400000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63125000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46400000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6535000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23961000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21890000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3083000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32069000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23099000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3253000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.05
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
16997000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
34520000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25813000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3636000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
16000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
12000
CY2021 imab Operating Lease Interest Expense
OperatingLeaseInterestExpense
2585000
CY2022 imab Operating Lease Interest Expense
OperatingLeaseInterestExpense
3178000
CY2023 imab Operating Lease Interest Expense
OperatingLeaseInterestExpense
2173000
CY2023 imab Operating Lease Interest Expense
OperatingLeaseInterestExpense
306000
CY2021 us-gaap Lease Cost
LeaseCost
19598000
CY2022 us-gaap Lease Cost
LeaseCost
37710000
CY2023 us-gaap Lease Cost
LeaseCost
27986000
CY2023 us-gaap Lease Cost
LeaseCost
3942000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
22949000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3232000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6202000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
873000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6378000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
898000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6562000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
924000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3087000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
435000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4825000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
680000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
50003000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7042000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5014000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
705000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6846000
CY2022Q4 imab Accrued External Research And Development Activities Related Expenses Current
AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
264972000
CY2023Q4 imab Accrued External Research And Development Activities Related Expenses Current
AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
181232000
CY2023Q4 imab Accrued External Research And Development Activities Related Expenses Current
AccruedExternalResearchAndDevelopmentActivitiesRelatedExpensesCurrent
25526000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
64782000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
35058000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4938000
CY2022Q4 imab Accrued Termination Fee And Other Expenses In Relation To Disputes With Tracon
AccruedTerminationFeeAndOtherExpensesInRelationToDisputesWithTracon
161106000
CY2022Q4 imab Non Refundable Incentive Payment From Depositary Bank Current
NonRefundableIncentivePaymentFromDepositaryBankCurrent
6428000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
44989000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6337000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
122000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3112000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
118888000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
122000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3890000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
118110000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
16635000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
778000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q4 us-gaap Goodwill
Goodwill
162574000
CY2022 imab Period Of Financial Projections For Calculating Value In Use
PeriodOfFinancialProjectionsForCalculatingValueInUse
P10Y
CY2023 imab Period Of Financial Projections For Calculating Value In Use
PeriodOfFinancialProjectionsForCalculatingValueInUse
P10Y
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
162574000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
22898000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
43483000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
48604000
CY2023Q4 imab Non Refundable Incentive Payment From Depositary Bank Current
NonRefundableIncentivePaymentFromDepositaryBankCurrent
9014000
CY2023Q4 imab Non Refundable Incentive Payment From Depositary Bank Current
NonRefundableIncentivePaymentFromDepositaryBankCurrent
1270000
CY2022Q4 imab Purchase Of Property Equipment And Software Payable Current
PurchaseOfPropertyEquipmentAndSoftwarePayableCurrent
7124000
CY2023Q4 imab Purchase Of Property Equipment And Software Payable Current
PurchaseOfPropertyEquipmentAndSoftwarePayableCurrent
1226000
CY2023Q4 imab Purchase Of Property Equipment And Software Payable Current
PurchaseOfPropertyEquipmentAndSoftwarePayableCurrent
173000
CY2022Q4 imab Accrued Travelling Expenses Office Expenses And Others
AccruedTravellingExpensesOfficeExpensesAndOthers
158677000
CY2023Q4 imab Accrued Travelling Expenses Office Expenses And Others
AccruedTravellingExpensesOfficeExpensesAndOthers
82620000
CY2023Q4 imab Accrued Travelling Expenses Office Expenses And Others
AccruedTravellingExpensesOfficeExpensesAndOthers
11636000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
706572000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
357754000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50389000
CY2022Q4 imab Non Refundable Incentive Payment From Depositary Bank Noncurrent
NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
6963000
CY2023Q4 imab Non Refundable Incentive Payment From Depositary Bank Noncurrent
NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
751000
CY2023Q4 imab Non Refundable Incentive Payment From Depositary Bank Noncurrent
NonRefundableIncentivePaymentFromDepositaryBankNoncurrent
105000
CY2022Q4 imab Non Refundable Payments Received In Relation To Exclusive Promotion Right Granted To Third Party
NonRefundablePaymentsReceivedInRelationToExclusivePromotionRightGrantedToThirdParty
10000000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
124733000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
17569000
CY2021 imab Effective Income Tax Rate Reconciliation Deductible Expense Research And Development Amount
EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
50530000
CY2022 imab Effective Income Tax Rate Reconciliation Deductible Expense Research And Development Amount
EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
74415000
CY2023 imab Effective Income Tax Rate Reconciliation Deductible Expense Research And Development Amount
EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
80069000
CY2023 imab Effective Income Tax Rate Reconciliation Deductible Expense Research And Development Amount
EffectiveIncomeTaxRateReconciliationDeductibleExpenseResearchAndDevelopmentAmount
11278000
CY2021 imab True Up Of Withholding Tax Expenses
TrueUpOfWithholdingTaxExpenses
-3154000
CY2023Q4 imab Non Refundable Payments Received In Relation To Exclusive Promotion Right Granted To Third Party
NonRefundablePaymentsReceivedInRelationToExclusivePromotionRightGrantedToThirdParty
10000000
CY2023Q4 imab Non Refundable Payments Received In Relation To Exclusive Promotion Right Granted To Third Party
NonRefundablePaymentsReceivedInRelationToExclusivePromotionRightGrantedToThirdParty
1408000
CY2023Q4 us-gaap Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
58913000
CY2023Q4 us-gaap Supplier Finance Program Obligation Noncurrent
SupplierFinanceProgramObligationNoncurrent
8298000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
16963000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
69664000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
9811000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
723535000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
427418000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
60200000
CY2020Q2 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
1857000
CY2020Q2 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
12982000
CY2022 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
1195000
CY2022 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
8075000
CY2023Q1 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
671000
CY2023Q1 imab Proceeds From Non Refundable Incentive
ProceedsFromNonRefundableIncentive
4734000
CY2021 us-gaap Other Income
OtherIncome
2395000
CY2022 us-gaap Other Income
OtherIncome
2821000
CY2023 us-gaap Other Income
OtherIncome
8569000
CY2021Q4 imab Proceeds From Non Refundable Payment
ProceedsFromNonRefundablePayment
10000000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0825
CY2020 imab Withholding Tax
WithholdingTax
12231000
CY2021 imab Payment Of Withholding Taxes To Tax Authorities
PaymentOfWithholdingTaxesToTaxAuthorities
9077000
CY2021 imab Withholding Tax
WithholdingTax
-3154000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2334695000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2506620000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1465694000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-206439000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-410899000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-442343000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-263660000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-37136000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
68400000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
38570000
CY2022 imab True Up Of Withholding Tax Expenses
TrueUpOfWithholdingTaxExpenses
0
CY2023 imab True Up Of Withholding Tax Expenses
TrueUpOfWithholdingTaxExpenses
0
CY2023 imab True Up Of Withholding Tax Expenses
TrueUpOfWithholdingTaxExpenses
0
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
393029000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
478885000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
218996000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
30845000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3154000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
697000
CY2021 imab Income Tax Holiday Income Tax Benefit Per Share
IncomeTaxHolidayIncomeTaxBenefitPerShare
-0.84
CY2022 imab Income Tax Holiday Income Tax Benefit Per Share
IncomeTaxHolidayIncomeTaxBenefitPerShare
-0.65
CY2023 imab Income Tax Holiday Income Tax Benefit Per Share
IncomeTaxHolidayIncomeTaxBenefitPerShare
-0.42
CY2023 imab Income Tax Holiday Income Tax Benefit Per Share
IncomeTaxHolidayIncomeTaxBenefitPerShare
-0.06
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
792602000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
912137000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
128472000
CY2022Q4 imab Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
39189000
CY2023Q4 imab Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
91214000
CY2023Q4 imab Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
12847000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
127950000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
197274000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
27785000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
30210000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
8205000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1156000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
972118000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1191114000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
167765000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
17833000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
17716000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2495000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
17833000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
17716000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2495000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
17833000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
17716000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2495000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
100204000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
493233000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
972118000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
136920000
CY2021 imab Deferred Taxes Additions Valuation Allowance
DeferredTaxesAdditionsValuationAllowance
-393029000
CY2022 imab Deferred Taxes Additions Valuation Allowance
DeferredTaxesAdditionsValuationAllowance
-478885000
CY2023 imab Deferred Taxes Additions Valuation Allowance
DeferredTaxesAdditionsValuationAllowance
-283273000
CY2023 imab Deferred Taxes Additions Valuation Allowance
DeferredTaxesAdditionsValuationAllowance
-39898000
CY2023 imab Deferred Tax Assets Valuation Allowance Utilization And Reversal
DeferredTaxAssetsValuationAllowanceUtilizationAndReversal
64277000
CY2023 imab Deferred Tax Assets Valuation Allowance Utilization And Reversal
DeferredTaxAssetsValuationAllowanceUtilizationAndReversal
9053000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
493233000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
972118000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1191114000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
167765000
CY2023Q4 imab Common Stock Value Authorized
CommonStockValueAuthorized
80000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164888519
CY2021 imab Exercise Of Warrants Shares
ExerciseOfWarrantsShares
5341267
CY2023Q3 dei Entity Listing Depository Receipt Ratio
EntityListingDepositoryReceiptRatio
2.3
CY2023Q3 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P12M
CY2022 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1652541
CY2023 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
10656794
CY2023 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
8600000
CY2023 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
61260000
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8227843
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6845888
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
280568
CY2021 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
5369140
CY2022 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
1859819
CY2023 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
1260701
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
621876000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371000000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
197817000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27862000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
91024000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12820000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M25D
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
9000000.0
CY2022 imab Termination Fees
TerminationFees
600000
CY2022 imab Termination Fees
TerminationFees
4200000
CY2021 imab Recognition Revenue In Year
RecognitionRevenueInYear
31615000
CY2022 imab Recognition Revenue In Year
RecognitionRevenueInYear
39891000
CY2023 imab Recognition Revenue In Year
RecognitionRevenueInYear
16814000
CY2023 imab Recognition Revenue In Year
RecognitionRevenueInYear
2368000
CY2022 imab Reduction Revenue In Year
ReductionRevenueInYear
-314181000
CY2021 imab Licensing And Collaboration Revenue
LicensingAndCollaborationRevenue
40115000
CY2022 imab Licensing And Collaboration Revenue
LicensingAndCollaborationRevenue
-249665000
CY2023 imab Licensing And Collaboration Revenue
LicensingAndCollaborationRevenue
16814000
CY2023 imab Licensing And Collaboration Revenue
LicensingAndCollaborationRevenue
2368000
CY2021 imab Incentive Income From Depository Bank
IncentiveIncomeFromDepositoryBank
2395000
CY2022 imab Incentive Income From Depository Bank
IncentiveIncomeFromDepositoryBank
2821000
CY2023 imab Incentive Income From Depository Bank
IncentiveIncomeFromDepositoryBank
8569000
CY2023 imab Incentive Income From Depository Bank
IncentiveIncomeFromDepositoryBank
1207000
CY2021 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-30360000
CY2022 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
13549000
CY2023 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-26461000
CY2023 imab Fair Value Change Of Short Term Investments
FairValueChangeOfShortTermInvestments
-3727000
CY2021 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
-16628000
CY2022 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
-34260000
CY2023 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
7888000
CY2023 imab Fair Value Adjustments Of Put Right Liabilities
FairValueAdjustmentsOfPutRightLiabilities
1111000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
25373000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-175391000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-60704000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8550000
CY2021 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
9216000
CY2022 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
25470000
CY2023 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
5354000
CY2023 us-gaap Charity Care Reimbursements Received
CharityCareReimbursementsReceived
754000
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-7905000
CY2023 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
-1113000
CY2021 imab Other Income Expenses
OtherIncomeExpenses
-810000
CY2022 imab Other Income Expenses
OtherIncomeExpenses
-198000
CY2023 imab Other Income Expenses
OtherIncomeExpenses
-1996000
CY2023 imab Other Income Expenses
OtherIncomeExpenses
-282000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
83162000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-126587000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38109000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5368000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-2331541000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2507317000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1465694000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-206439000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2331541000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2507317000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1465694000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-206439000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174707055
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189787292
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
191423850
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
191423850
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174707055
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189787292
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191423850
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
191423850
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.35
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.35
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.21
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.21
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.66
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.66
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
26426000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
35332000
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
26401000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4392000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2023Q4 imab Statutory Reserve Annual Appropriation Percentage From After Tax Profit
StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit
0.10
CY2023Q4 imab Threshold Percentage Of General Reserve To Registered Capital For Reserve Appropriation
ThresholdPercentageOfGeneralReserveToRegisteredCapitalForReserveAppropriation
0.50
CY2021 imab Appropriationto Statutory Reserve
AppropriationtoStatutoryReserve
0
CY2022 imab Appropriationto Statutory Reserve
AppropriationtoStatutoryReserve
0
CY2023 imab Appropriationto Statutory Reserve
AppropriationtoStatutoryReserve
0
CY2023Q4 imab Statutory Reserve Annual Appropriation Percentage From After Tax Profit
StatutoryReserveAnnualAppropriationPercentageFromAfterTaxProfit
0.10

Files In Submission

Name View Source Status
0001104659-24-054452-index-headers.html Edgar Link pending
0001104659-24-054452-index.html Edgar Link pending
0001104659-24-054452.txt Edgar Link pending
0001104659-24-054452-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
imab-20231231.xsd Edgar Link pending
imab-20231231x20f.htm Edgar Link pending
imab-20231231x20f009.jpg Edgar Link pending
imab-20231231x20f011.jpg Edgar Link pending
imab-20231231x20f013.jpg Edgar Link pending
imab-20231231x20f015.jpg Edgar Link pending
imab-20231231x20f017.jpg Edgar Link pending
imab-20231231x20f019.jpg Edgar Link pending
imab-20231231x20f021.jpg Edgar Link pending
imab-20231231x20f023.jpg Edgar Link pending
imab-20231231x20f025.jpg Edgar Link pending
imab-20231231x20f026.jpg Edgar Link pending
imab-20231231x20f028.jpg Edgar Link pending
imab-20231231x20f030.jpg Edgar Link pending
imab-20231231xex12d1.htm Edgar Link pending
imab-20231231xex12d2.htm Edgar Link pending
imab-20231231xex13d1.htm Edgar Link pending
imab-20231231x20f_htm.xml Edgar Link completed
imab-20231231xex13d2.htm Edgar Link pending
imab-20231231xex15d1.htm Edgar Link pending
imab-20231231xex15d1001.jpg Edgar Link pending
imab-20231231xex15d2.htm Edgar Link pending
imab-20231231xex15d3.htm Edgar Link pending
imab-20231231xex15d3001.jpg Edgar Link pending
imab-20231231xex8d1.htm Edgar Link pending
imab-20231231xex97d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
imab-20231231_def.xml Edgar Link unprocessable
imab-20231231_lab.xml Edgar Link unprocessable
imab-20231231_pre.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
imab-20231231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable